SPTLC2-driven sphingolipid reprogramming of neutrophils impairs anti-tumour immunity and drives liver cancer progression.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.